The health care costs of heart failure in Sweden

被引:117
作者
Rydén-Bergsten, T [1 ]
Andersson, F
机构
[1] AstraZeneca R&D, Dept Hlth Econ, S-43183 Molndal, Sweden
[2] AstraZeneca R&D, Dept Hlth Econ & Qual Life, Lund, Sweden
关键词
cost-of-illness; heart failure; total treatment costs;
D O I
10.1046/j.1365-2796.1999.00520.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim. Heart failure is a common and serious condition requiring extensive health care resources. The aim of this study is to estimate the total treatment costs of heart failure in Sweden. Methods and results. The study is a prevalence-based cost-of-illness study. It includes costs of institutional care (hospitals and nursing homes), outpatient care, surgery and drugs. The costs are estimated based on official Swedish statistics, and on various clinical and epidemiological studies. The results are expressed in 1996 prices. The total annual treatment costs for heart failure are approximately Swedish kronor (SEK) 2000-2600 million, or nearly 2% of the Swedish health care budget. Institutional care is the single largest component, amounting to SEI( 1300-1900 million, or about 65-75% of the costs of heart failure treatment. Conclusions. The results from this study indicate that heart failure is a costly condition. Efforts to develop effective management programmes that can reduce the need for expensive institutional care, without a negative impact on quality of life, morbidity and mortality, should be given high priority.
引用
收藏
页码:275 / 284
页数:10
相关论文
共 43 条
[1]   THE COST OF ANGINA-PECTORIS IN SWEDEN [J].
ANDERSSON, F ;
KARTMAN, B .
PHARMACOECONOMICS, 1995, 8 (03) :233-244
[2]   Cost effective management programme for heart failure reduces hospitalisation [J].
Cline, CMJ ;
Israelsson, BYA ;
Willenheimer, RB ;
Broms, K ;
Erhardt, LR .
HEART, 1998, 80 (05) :442-446
[3]   A COMPARISON OF ENALAPRIL WITH HYDRALAZINE ISOSORBIDE DINITRATE IN THE TREATMENT OF CHRONIC CONGESTIVE-HEART-FAILURE [J].
COHN, JN ;
JOHNSON, G ;
ZIESCHE, S ;
COBB, F ;
FRANCIS, G ;
TRISTANI, F ;
SMITH, R ;
DUNKMAN, WB ;
LOEB, H ;
WONG, ML ;
BHAT, G ;
GOLDMAN, S ;
FLETCHER, RD ;
DOHERTY, J ;
HUGHES, CV ;
CARSON, P ;
CINTRON, G ;
SHABETAI, R ;
HAAKENSON, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (05) :303-310
[4]   THE DEFINITION OF HEART-FAILURE [J].
DENOLIN, H ;
KUHN, H ;
KRAYENBUEHL, HP ;
LOOGEN, F ;
REALE, A .
EUROPEAN HEART JOURNAL, 1983, 4 (07) :445-448
[5]  
DOUGHTY R, 1995, NEW ZEAL MED J, V108, P473
[6]  
ERHARDT L, 1994, HEART FAILURE, P3
[7]   HEART-FAILURE - A GROWING PUBLIC-HEALTH PROBLEM [J].
ERIKSSON, H .
JOURNAL OF INTERNAL MEDICINE, 1995, 237 (02) :135-141
[8]  
ERIKSSON H, 1988, ACTA MED SCAND, V223, P197
[9]   Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure [J].
Fonarow, GC ;
Stevenson, LW ;
Walden, JA ;
Livingston, NA ;
Steimle, AE ;
Hamilton, MA ;
Moriguchi, J ;
Tillisch, JH ;
Woo, MA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (03) :725-732
[10]   EPIDEMIOLOGY OF HEART-FAILURE IN THE UNITED-STATES [J].
GILLUM, RF .
AMERICAN HEART JOURNAL, 1993, 126 (04) :1042-1047